Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492349 · ClinicalTrials.gov registry record · Phase 4
Varenicline Adjunctive Treatment in Schizophrenia
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT00492349 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 91 participants.
The verdict
NCT00492349, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients.
Interventions
- DRUG Placebo
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492349
The ClinicalTrials.gov registry entry for NCT00492349 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00492349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492349 about?
NCT00492349 is a clinical study titled "Varenicline Adjunctive Treatment in Schizophrenia". The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients.
What is the current status of trial NCT00492349?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2007-05. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00492349?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00492349?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.